{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:53:02Z","timestamp":1777953182542,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11486-6","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T11:43:41Z","timestamp":1772019821000},"page":"2731-2748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["AI-driven generative framework integrating ML-QSAR and fragment learning for isoform-selective PI3K inhibitor design"],"prefix":"10.1007","volume":"30","author":[{"given":"Harshit","family":"Sajal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aswin","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh","family":"Raju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5231-6678","authenticated-orcid":false,"given":"Anuroopa G.","family":"Nadh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"11486_CR1","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY et al (2023) PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer 22:138. https:\/\/doi.org\/10.1186\/s12943-023-01827-6","journal-title":"Mol Cancer"},{"key":"11486_CR2","doi-asserted-by":"publisher","first-page":"606","DOI":"10.3892\/ijo.2016.3804","volume":"50","author":"Y Wang","year":"2017","unstructured":"Wang Y, Kuramitsu Y, Baron B et al (2017) PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int J Oncol 50:606\u2013612. https:\/\/doi.org\/10.3892\/ijo.2016.3804","journal-title":"Int J Oncol"},{"key":"11486_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12943-024-02072-1","volume":"23","author":"H Li","year":"2024","unstructured":"Li H, Wen X, Ren Y et al (2024) Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions. Mol Cancer 23:164. https:\/\/doi.org\/10.1186\/s12943-024-02072-1","journal-title":"Mol Cancer"},{"key":"11486_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.tips.2023.06.002","volume":"44","author":"D Cirillo","year":"2023","unstructured":"Cirillo D, Diceglie M, Nazar\u00e9 M (2023) Isoform-selective targeting of PI3K: time to consider new opportunities? Trends Pharmacol Sci 44:601\u2013621. https:\/\/doi.org\/10.1016\/j.tips.2023.06.002","journal-title":"Trends Pharmacol Sci"},{"key":"11486_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","volume":"20","author":"B Vanhaesebroeck","year":"2021","unstructured":"Vanhaesebroeck B, Perry MWD, Brown JR et al (2021) PI3K inhibitors are finally coming of age. Nat Rev Drug Discov 20:741\u2013769. https:\/\/doi.org\/10.1038\/s41573-021-00209-1","journal-title":"Nat Rev Drug Discov"},{"key":"11486_CR6","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nrc2443","volume":"8","author":"LM Amzel","year":"2008","unstructured":"Amzel LM, Huang C-H, Mandelker D et al (2008) Structural comparisons of class I phosphoinositide 3-kinases. Nat Rev Cancer 8:665\u2013669. https:\/\/doi.org\/10.1038\/nrc2443","journal-title":"Nat Rev Cancer"},{"key":"11486_CR7","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/biom9030082","volume":"9","author":"M Miller","year":"2019","unstructured":"Miller M, Thompson P, Gabelli S (2019) Structural determinants of isoform selectivity in PI3K inhibitors. Biomolecules 9:82. https:\/\/doi.org\/10.3390\/biom9030082","journal-title":"Biomolecules"},{"key":"11486_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/14656566.2021.1873952","volume":"22","author":"F Leenhardt","year":"2021","unstructured":"Leenhardt F, Alexandre M, Jacot W (2021) Alpelisib for the treatment of PIK3CA -mutated, hormone receptor-positive, HER2-negative metastatic breast cancer. Expert Opin Pharmacother 22:667\u2013675. https:\/\/doi.org\/10.1080\/14656566.2021.1873952","journal-title":"Expert Opin Pharmacother"},{"key":"11486_CR9","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.hoc.2021.03.009","volume":"35","author":"BL Lampson","year":"2021","unstructured":"Lampson BL, Brown JR (2021) The evolving use of phosphatidylinositol 3-kinase inhibitors for the treatment of chronic lymphocytic leukemia. Hematol Oncol Clin North Am 35:807\u2013826. https:\/\/doi.org\/10.1016\/j.hoc.2021.03.009","journal-title":"Hematol Oncol Clin North Am"},{"key":"11486_CR10","doi-asserted-by":"publisher","first-page":"6090","DOI":"10.1038\/s41598-022-09843-0","volume":"12","author":"F Sadeghi","year":"2022","unstructured":"Sadeghi F, Afkhami A, Madrakian T, Ghavami R (2022) QSAR analysis on a large and diverse set of potent phosphoinositide 3-kinase gamma (PI3K\u03b3) inhibitors using MLR and ANN methods. Sci Rep 12:6090. https:\/\/doi.org\/10.1038\/s41598-022-09843-0","journal-title":"Sci Rep"},{"key":"11486_CR11","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1021\/acs.jcim.4c00234","volume":"64","author":"R Chandraghatgi","year":"2024","unstructured":"Chandraghatgi R, Ji H-F, Rosen GL, Sokhansanj BA (2024) Streamlining computational fragment-based drug discovery through evolutionary optimization informed by ligand-based virtual prescreening. J Chem Inf Model 64:3826\u20133840. https:\/\/doi.org\/10.1021\/acs.jcim.4c00234","journal-title":"J Chem Inf Model"},{"key":"11486_CR12","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107 M, Djikic-Stojsic T, Nikolic K (2025) A Computational framework for the design and development of isoform selective PI3K\u03b1 inhibitors as novel anticancer agents","DOI":"10.26434\/chemrxiv-2025-5kh41-v2"},{"key":"11486_CR13","doi-asserted-by":"publisher","first-page":"11488","DOI":"10.3390\/ijms241411488","volume":"24","author":"SK Niazi","year":"2023","unstructured":"Niazi SK, Mariam Z (2023) Recent advances in machine-learning-based chemoinformatics: a comprehensive review. Int J Mol Sci 24:11488. https:\/\/doi.org\/10.3390\/ijms241411488","journal-title":"Int J Mol Sci"},{"key":"11486_CR14","doi-asserted-by":"publisher","first-page":"103052","DOI":"10.1016\/j.isci.2021.103052","volume":"24","author":"J Mao","year":"2021","unstructured":"Mao J, Akhtar J, Zhang X et al (2021) Comprehensive strategies of machine-learning-based quantitative structure-activity relationship models. iScience 24:103052. https:\/\/doi.org\/10.1016\/j.isci.2021.103052","journal-title":"iScience"},{"key":"11486_CR15","unstructured":"Telepov A, Tsypin A, Khrabrov K, et al (2024) FREED++: improving RL agents for fragment-based molecule generation by thorough reproduction"},{"key":"11486_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s11030-025-11281-9","author":"H Sajal","year":"2025","unstructured":"Sajal H, Mishra S (2025) An innovative machine learning-based QSAR approach for prediction and structural analysis of novel\/repurposed acid ceramidase (ASAH1) inhibitors for glioblastoma therapy. Mol Divers. https:\/\/doi.org\/10.1007\/s11030-025-11281-9","journal-title":"Mol Divers"},{"key":"11486_CR17","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.toxlet.2023.01.006","volume":"376","author":"C Gui","year":"2023","unstructured":"Gui C, Li Y, Peng T (2023) Development of predictive QSAR models for the substrates\/inhibitors of OATP1B1 by deep neural networks. Toxicol Lett 376:20\u201325. https:\/\/doi.org\/10.1016\/j.toxlet.2023.01.006","journal-title":"Toxicol Lett"},{"key":"11486_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3103\/S0027131419010036","volume":"74","author":"LD Grigoreva","year":"2019","unstructured":"Grigoreva LD, Grigorev VY, Yarkov AV (2019) Outlier detection in QSAR modeling of the biological activity of chemicals by analyzing the structure\u2013activity\u2013similarity maps. Moscow Univ Chem Bull 74:1\u20139. https:\/\/doi.org\/10.3103\/S0027131419010036","journal-title":"Moscow Univ Chem Bull"},{"key":"11486_CR19","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1016\/j.bmc.2005.05.002","volume":"13","author":"RP Verma","year":"2005","unstructured":"Verma RP, Hansch C (2005) An approach toward the problem of outliers in QSAR. Bioorg Med Chem 13:4597\u20134621. https:\/\/doi.org\/10.1016\/j.bmc.2005.05.002","journal-title":"Bioorg Med Chem"},{"key":"11486_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13321-024-00894-1","volume":"16","author":"JT Moreira-Filho","year":"2024","unstructured":"Moreira-Filho JT, Ranganath D, Conway M et al (2024) Democratizing cheminformatics: interpretable chemical grouping using an automated KNIME workflow. J Cheminform 16:101. https:\/\/doi.org\/10.1186\/s13321-024-00894-1","journal-title":"J Cheminform"},{"key":"11486_CR21","doi-asserted-by":"publisher","first-page":"131249","DOI":"10.1016\/j.molstruc.2021.131249","volume":"1244","author":"J Li","year":"2021","unstructured":"Li J, Luo D, Wen T et al (2021) Representative feature selection of molecular descriptors in QSAR modeling. J Mol Struct 1244:131249. https:\/\/doi.org\/10.1016\/j.molstruc.2021.131249","journal-title":"J Mol Struct"},{"key":"11486_CR22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s42004-024-01109-2","volume":"7","author":"S Jinsong","year":"2024","unstructured":"Jinsong S, Qifeng J, Xing C et al (2024) Molecular fragmentation as a crucial step in the AI-based drug development pathway. Commun Chem 7:20. https:\/\/doi.org\/10.1038\/s42004-024-01109-2","journal-title":"Commun Chem"},{"key":"11486_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s13659-025-00521-y","volume":"15","author":"C-S Liu","year":"2025","unstructured":"Liu C-S, Yan B-C, Sun H-D et al (2025) Bridging chemical space and biological efficacy: advances and challenges in applying generative models in structural modification of natural products. Nat Prod Bioprospect 15:37. https:\/\/doi.org\/10.1007\/s13659-025-00521-y","journal-title":"Nat Prod Bioprospect"},{"key":"11486_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13321-024-00812-5","volume":"16","author":"HH Loeffler","year":"2024","unstructured":"Loeffler HH, He J, Tibo A et al (2024) Reinvent 4: modern AI\u2013driven generative molecule design. J Cheminform 16:20. https:\/\/doi.org\/10.1186\/s13321-024-00812-5","journal-title":"J Cheminform"},{"key":"11486_CR25","doi-asserted-by":"publisher","first-page":"101674","DOI":"10.1016\/j.jics.2025.101674","volume":"102","author":"AG Nadh","year":"2025","unstructured":"Nadh AG, Amjesh R, Ahmed M et al (2025) Identification of high-affinity molecules from Sesbania grandiflora as potential therapeutic agents for oral ulcers\u2014a multi-target-directed in silico approach. J Indian Chem Soc 102:101674. https:\/\/doi.org\/10.1016\/j.jics.2025.101674","journal-title":"J Indian Chem Soc"},{"key":"11486_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s13765-024-00930-6","volume":"67","author":"B Abera","year":"2024","unstructured":"Abera B, Melaku Y, Shenkute K et al (2024) In vitro antibacterial, antioxidant, in silico molecular docking and ADEMT analysis of chemical constituents from the roots of Acokanthera schimperi and Rhus glutinosa. Appl Biol Chem 67:77. https:\/\/doi.org\/10.1186\/s13765-024-00930-6","journal-title":"Appl Biol Chem"},{"key":"11486_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa321","author":"Z Wu","year":"2021","unstructured":"Wu Z, Zhu M, Kang Y et al (2021) Do we need different machine learning algorithms for QSAR modeling? A comprehensive assessment of 16 machine learning algorithms on 14 QSAR data sets. Brief Bioinform. https:\/\/doi.org\/10.1093\/bib\/bbaa321","journal-title":"Brief Bioinform"},{"key":"11486_CR28","doi-asserted-by":"publisher","first-page":"12150","DOI":"10.1038\/s41598-021-90287-3","volume":"11","author":"BV Bhaskar","year":"2021","unstructured":"Bhaskar BV, Rammohan A, Babu TM et al (2021) Molecular insight into isoform specific inhibition of PI3K-\u03b1 and PKC-\u03b7 with dietary agents through an ensemble pharmacophore and docking studies. Sci Rep 11:12150. https:\/\/doi.org\/10.1038\/s41598-021-90287-3","journal-title":"Sci Rep"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11486-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11486-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T14:26:20Z","timestamp":1777904780000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11486-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["11486"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11486-6","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}